Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Arthritis, Rheumatoid | 31 | 2024 | 3781 | 1.860 |
Why?
|
Antirheumatic Agents | 20 | 2024 | 1381 | 1.640 |
Why?
|
Lupus Erythematosus, Systemic | 25 | 2024 | 2171 | 1.630 |
Why?
|
Lupus Nephritis | 6 | 2024 | 327 | 0.560 |
Why?
|
Hydroxychloroquine | 5 | 2015 | 426 | 0.530 |
Why?
|
Fever of Unknown Origin | 1 | 2016 | 94 | 0.530 |
Why?
|
Rheumatic Diseases | 7 | 2021 | 659 | 0.490 |
Why?
|
Rheumatology | 5 | 2021 | 617 | 0.440 |
Why?
|
Leiomyosarcoma | 1 | 2016 | 426 | 0.400 |
Why?
|
Immunoglobulin Fab Fragments | 2 | 2012 | 446 | 0.380 |
Why?
|
PPAR gamma | 1 | 2013 | 486 | 0.340 |
Why?
|
Thiazolidinediones | 1 | 2013 | 461 | 0.330 |
Why?
|
Complement C3 | 3 | 2020 | 434 | 0.330 |
Why?
|
Complement Activation | 3 | 2020 | 447 | 0.320 |
Why?
|
Immunoconjugates | 4 | 2008 | 975 | 0.290 |
Why?
|
Glucocorticoids | 3 | 2016 | 2167 | 0.290 |
Why?
|
Uterine Neoplasms | 1 | 2016 | 1424 | 0.290 |
Why?
|
Polyethylene Glycols | 2 | 2012 | 1196 | 0.280 |
Why?
|
Chemokine CXCL13 | 2 | 2024 | 62 | 0.260 |
Why?
|
Complement C4 | 3 | 2020 | 216 | 0.240 |
Why?
|
Antibodies, Antinuclear | 7 | 2021 | 342 | 0.220 |
Why?
|
Insulin Resistance | 3 | 2014 | 3986 | 0.220 |
Why?
|
Lupus Erythematosus, Discoid | 2 | 2015 | 61 | 0.220 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2024 | 287 | 0.220 |
Why?
|
Synovial Fluid | 6 | 2023 | 393 | 0.220 |
Why?
|
Arthritis, Infectious | 2 | 2002 | 348 | 0.220 |
Why?
|
Lipids | 1 | 2014 | 3343 | 0.210 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 2011 | 4352 | 0.210 |
Why?
|
Coronary Circulation | 3 | 2024 | 1617 | 0.210 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2024 | 221 | 0.200 |
Why?
|
Arteritis | 1 | 2024 | 159 | 0.190 |
Why?
|
Lyme Disease | 2 | 2002 | 630 | 0.190 |
Why?
|
Complement C4b | 2 | 2019 | 124 | 0.190 |
Why?
|
Drug Substitution | 1 | 2024 | 291 | 0.180 |
Why?
|
Antibodies, Monoclonal | 5 | 2017 | 9263 | 0.180 |
Why?
|
Disease Progression | 5 | 2019 | 13671 | 0.180 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2024 | 4415 | 0.180 |
Why?
|
Europe | 4 | 2019 | 3436 | 0.180 |
Why?
|
Arthritis, Psoriatic | 1 | 2023 | 219 | 0.180 |
Why?
|
Societies, Medical | 4 | 2019 | 3968 | 0.170 |
Why?
|
Interferon Type I | 1 | 2024 | 569 | 0.170 |
Why?
|
Inflammation | 6 | 2024 | 10873 | 0.160 |
Why?
|
Microcirculation | 1 | 2024 | 1281 | 0.160 |
Why?
|
Lymphoma, B-Cell | 1 | 2005 | 945 | 0.160 |
Why?
|
Macrophage Activation | 1 | 2022 | 557 | 0.160 |
Why?
|
Myocardial Perfusion Imaging | 2 | 2024 | 672 | 0.160 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 1143 | 0.150 |
Why?
|
HLA-DR Antigens | 3 | 2018 | 609 | 0.140 |
Why?
|
Middle Aged | 44 | 2024 | 223492 | 0.140 |
Why?
|
Humans | 74 | 2024 | 768166 | 0.140 |
Why?
|
Spin Labels | 1 | 2019 | 336 | 0.140 |
Why?
|
Pain Measurement | 2 | 2019 | 3583 | 0.140 |
Why?
|
T-Lymphocytes, Helper-Inducer | 2 | 2024 | 977 | 0.130 |
Why?
|
Medication Adherence | 2 | 2018 | 2187 | 0.130 |
Why?
|
Bacteria, Anaerobic | 1 | 1996 | 71 | 0.130 |
Why?
|
Anorexia | 1 | 2016 | 153 | 0.130 |
Why?
|
B-Lymphocytes | 4 | 2020 | 4793 | 0.130 |
Why?
|
Severity of Illness Index | 6 | 2020 | 15948 | 0.130 |
Why?
|
Bursitis | 1 | 1996 | 85 | 0.120 |
Why?
|
Liver Function Tests | 1 | 2016 | 526 | 0.120 |
Why?
|
Female | 49 | 2024 | 397192 | 0.120 |
Why?
|
Clinical Trials as Topic | 2 | 2008 | 8054 | 0.120 |
Why?
|
Interferon-alpha | 2 | 2017 | 910 | 0.120 |
Why?
|
Biological Products | 1 | 2024 | 948 | 0.120 |
Why?
|
Peptides, Cyclic | 2 | 2007 | 391 | 0.110 |
Why?
|
Cyclopropanes | 1 | 2015 | 436 | 0.110 |
Why?
|
Methotrexate | 5 | 2012 | 1721 | 0.110 |
Why?
|
Peptide Fragments | 2 | 2019 | 5151 | 0.110 |
Why?
|
Male | 44 | 2024 | 364719 | 0.110 |
Why?
|
Coronary Vessels | 2 | 2024 | 3124 | 0.110 |
Why?
|
Sensitivity and Specificity | 8 | 2021 | 14729 | 0.110 |
Why?
|
Autoimmune Diseases | 1 | 2005 | 2257 | 0.110 |
Why?
|
Coronary Artery Disease | 3 | 2024 | 6568 | 0.110 |
Why?
|
Treatment Outcome | 16 | 2024 | 65371 | 0.110 |
Why?
|
Biopsy | 4 | 2019 | 6793 | 0.100 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4648 | 0.100 |
Why?
|
Cough | 1 | 2016 | 598 | 0.100 |
Why?
|
Molecular Imaging | 1 | 2019 | 826 | 0.100 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2005 | 696 | 0.100 |
Why?
|
Probenecid | 1 | 1992 | 73 | 0.100 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2019 | 794 | 0.100 |
Why?
|
Erythromycin | 1 | 1992 | 115 | 0.100 |
Why?
|
Receptors, Complement | 1 | 2012 | 254 | 0.100 |
Why?
|
Panniculitis | 1 | 2012 | 45 | 0.100 |
Why?
|
Erythrocytes | 3 | 2020 | 2418 | 0.100 |
Why?
|
Ferritins | 1 | 2015 | 601 | 0.100 |
Why?
|
Adult | 34 | 2024 | 223646 | 0.100 |
Why?
|
Rheumatoid Factor | 4 | 2019 | 185 | 0.100 |
Why?
|
Urban Health Services | 1 | 2012 | 177 | 0.100 |
Why?
|
Myocardial Ischemia | 1 | 2022 | 2138 | 0.090 |
Why?
|
Lupus Vasculitis, Central Nervous System | 1 | 2011 | 32 | 0.090 |
Why?
|
Cross-Over Studies | 2 | 2015 | 2107 | 0.090 |
Why?
|
Biological Therapy | 1 | 2012 | 140 | 0.090 |
Why?
|
Aged | 24 | 2024 | 171504 | 0.090 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2015 | 271 | 0.090 |
Why?
|
Joints | 1 | 2012 | 324 | 0.090 |
Why?
|
Hand | 1 | 1996 | 913 | 0.090 |
Why?
|
Amoxicillin | 1 | 1992 | 182 | 0.090 |
Why?
|
Models, Econometric | 2 | 2008 | 215 | 0.090 |
Why?
|
Blood Platelets | 2 | 2012 | 2479 | 0.090 |
Why?
|
Diagnosis, Differential | 4 | 2019 | 13014 | 0.090 |
Why?
|
Phospholipases A2, Secretory | 1 | 2010 | 30 | 0.090 |
Why?
|
T-Lymphocyte Subsets | 1 | 2018 | 1815 | 0.090 |
Why?
|
Double-Blind Method | 5 | 2015 | 12465 | 0.090 |
Why?
|
Medically Underserved Area | 1 | 2012 | 268 | 0.090 |
Why?
|
Cholecalciferol | 1 | 2015 | 557 | 0.090 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 12252 | 0.090 |
Why?
|
Doxycycline | 1 | 1992 | 349 | 0.080 |
Why?
|
Remission Induction | 2 | 2012 | 2410 | 0.080 |
Why?
|
Lichenoid Eruptions | 1 | 2009 | 13 | 0.080 |
Why?
|
Antigens | 1 | 2015 | 1442 | 0.080 |
Why?
|
Cytoskeletal Proteins | 1 | 2015 | 1327 | 0.080 |
Why?
|
Arthritis | 2 | 2010 | 684 | 0.080 |
Why?
|
Endocrine System Diseases | 1 | 2011 | 250 | 0.080 |
Why?
|
Dermatomyositis | 1 | 2012 | 259 | 0.080 |
Why?
|
Autoantibodies | 3 | 2019 | 2121 | 0.080 |
Why?
|
Disability Evaluation | 3 | 2011 | 1835 | 0.080 |
Why?
|
Listeriosis | 1 | 1990 | 147 | 0.080 |
Why?
|
Consensus | 1 | 2018 | 3212 | 0.080 |
Why?
|
Fractional Flow Reserve, Myocardial | 2 | 2024 | 346 | 0.080 |
Why?
|
Antigen-Antibody Complex | 1 | 2010 | 513 | 0.080 |
Why?
|
Cell-Derived Microparticles | 1 | 2010 | 160 | 0.080 |
Why?
|
Synovial Membrane | 3 | 2022 | 536 | 0.080 |
Why?
|
Bacterial Infections | 1 | 1996 | 1397 | 0.070 |
Why?
|
Hazardous Waste | 1 | 2007 | 23 | 0.070 |
Why?
|
C-Reactive Protein | 2 | 2024 | 3858 | 0.070 |
Why?
|
Kidney | 2 | 2019 | 7064 | 0.070 |
Why?
|
Pilot Projects | 4 | 2018 | 8741 | 0.070 |
Why?
|
Knee Prosthesis | 1 | 1990 | 395 | 0.070 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2019 | 2195 | 0.070 |
Why?
|
Antibodies, Anti-Idiotypic | 3 | 2015 | 355 | 0.070 |
Why?
|
HLA-DR3 Antigen | 1 | 2005 | 24 | 0.070 |
Why?
|
Psoriasis | 2 | 2011 | 926 | 0.060 |
Why?
|
Health Status Indicators | 1 | 2011 | 969 | 0.060 |
Why?
|
Morbidity | 1 | 2011 | 1755 | 0.060 |
Why?
|
Organogold Compounds | 1 | 2005 | 4 | 0.060 |
Why?
|
Insurance Claim Review | 1 | 2010 | 744 | 0.060 |
Why?
|
Interleukin-2 | 1 | 1992 | 1895 | 0.060 |
Why?
|
Flow Cytometry | 3 | 2020 | 5902 | 0.060 |
Why?
|
Glutathione Transferase | 1 | 2007 | 564 | 0.060 |
Why?
|
Young Adult | 10 | 2024 | 60066 | 0.060 |
Why?
|
Diabetes Mellitus | 3 | 2011 | 5889 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2009 | 1737 | 0.060 |
Why?
|
Receptors, Interleukin-6 | 1 | 2005 | 224 | 0.060 |
Why?
|
Genetic Markers | 1 | 2010 | 2603 | 0.060 |
Why?
|
Liver | 2 | 2016 | 7577 | 0.050 |
Why?
|
Epitopes | 2 | 2007 | 2528 | 0.050 |
Why?
|
United States | 7 | 2021 | 73039 | 0.050 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2005 | 458 | 0.050 |
Why?
|
Skin Diseases | 1 | 2011 | 1085 | 0.050 |
Why?
|
Gastrointestinal Diseases | 1 | 2011 | 1206 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2019 | 9419 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2015 | 4937 | 0.050 |
Why?
|
Work Capacity Evaluation | 1 | 2002 | 42 | 0.050 |
Why?
|
Case-Control Studies | 5 | 2021 | 22291 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15662 | 0.050 |
Why?
|
Mycophenolic Acid | 1 | 2024 | 348 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 2271 | 0.050 |
Why?
|
Collagen | 1 | 2010 | 2643 | 0.050 |
Why?
|
Cytokines | 2 | 2022 | 7453 | 0.050 |
Why?
|
Pain | 1 | 2016 | 5100 | 0.050 |
Why?
|
Gene Expression Regulation | 2 | 2019 | 11928 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2014 | 3620 | 0.050 |
Why?
|
Pregnancy Complications | 1 | 2015 | 2973 | 0.050 |
Why?
|
Lung Diseases | 1 | 2011 | 1944 | 0.050 |
Why?
|
Positron-Emission Tomography | 3 | 2024 | 6669 | 0.050 |
Why?
|
Granzymes | 1 | 2022 | 277 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2010 | 1805 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2011 | 2100 | 0.040 |
Why?
|
North America | 2 | 2018 | 1289 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2021 | 20760 | 0.040 |
Why?
|
Gene Expression Profiling | 3 | 2024 | 9538 | 0.040 |
Why?
|
Borrelia burgdorferi | 1 | 2002 | 183 | 0.040 |
Why?
|
Managed Care Programs | 1 | 2005 | 939 | 0.040 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 1 | 2019 | 40 | 0.040 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2019 | 72 | 0.040 |
Why?
|
Immunosuppressive Agents | 2 | 2024 | 4206 | 0.040 |
Why?
|
Troponin T | 1 | 2024 | 787 | 0.040 |
Why?
|
Immunologic Factors | 1 | 2008 | 1596 | 0.040 |
Why?
|
Single-Cell Analysis | 2 | 2022 | 2540 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 2496 | 0.040 |
Why?
|
Epigenomics | 1 | 2024 | 960 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2024 | 1027 | 0.040 |
Why?
|
Adolescent | 7 | 2024 | 89169 | 0.040 |
Why?
|
Multivariate Analysis | 4 | 2015 | 12077 | 0.040 |
Why?
|
Sjogren's Syndrome | 1 | 2019 | 240 | 0.040 |
Why?
|
Administration, Oral | 2 | 2018 | 4030 | 0.040 |
Why?
|
Macrophage-Activating Factors | 1 | 2017 | 21 | 0.040 |
Why?
|
Fibromyalgia | 1 | 2002 | 407 | 0.030 |
Why?
|
Adrenalectomy | 1 | 2019 | 348 | 0.030 |
Why?
|
Receptors, CXCR5 | 1 | 2017 | 88 | 0.030 |
Why?
|
Healthcare Disparities | 1 | 2012 | 3415 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2019 | 527 | 0.030 |
Why?
|
Urban Population | 1 | 2005 | 2046 | 0.030 |
Why?
|
Research Design | 1 | 2012 | 6211 | 0.030 |
Why?
|
Quality of Life | 5 | 2012 | 13490 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2021 | 990 | 0.030 |
Why?
|
Peptostreptococcus | 1 | 1996 | 27 | 0.030 |
Why?
|
Veillonella | 1 | 1996 | 21 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2015 | 10760 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 190 | 0.030 |
Why?
|
Polymyalgia Rheumatica | 1 | 1996 | 52 | 0.030 |
Why?
|
Lymphopenia | 1 | 2018 | 300 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4249 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2023 | 1801 | 0.030 |
Why?
|
Complement System Proteins | 1 | 2019 | 738 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 3 | 2007 | 18065 | 0.030 |
Why?
|
Interferons | 1 | 2019 | 720 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2024 | 1892 | 0.030 |
Why?
|
Delphi Technique | 1 | 2019 | 891 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2012 | 4916 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2012 | 5520 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2018 | 1353 | 0.030 |
Why?
|
Health Status | 1 | 2008 | 4091 | 0.030 |
Why?
|
Wrist | 1 | 1996 | 231 | 0.030 |
Why?
|
Cystectomy | 1 | 2019 | 603 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2022 | 4580 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2012 | 6395 | 0.030 |
Why?
|
Qualitative Research | 2 | 2018 | 3140 | 0.030 |
Why?
|
Cohort Studies | 5 | 2021 | 41754 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2019 | 1864 | 0.030 |
Why?
|
Population Surveillance | 1 | 2005 | 2596 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2019 | 839 | 0.030 |
Why?
|
Databases, Factual | 1 | 2010 | 8080 | 0.030 |
Why?
|
Self Report | 2 | 2015 | 3773 | 0.030 |
Why?
|
Osteoarthritis | 1 | 2002 | 1072 | 0.030 |
Why?
|
Follow-Up Studies | 5 | 2015 | 39348 | 0.030 |
Why?
|
Receptors, Chemokine | 1 | 2017 | 652 | 0.030 |
Why?
|
Azathioprine | 1 | 2015 | 354 | 0.030 |
Why?
|
Th1 Cells | 1 | 2018 | 1042 | 0.030 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 1996 | 342 | 0.030 |
Why?
|
Cell Differentiation | 2 | 2024 | 11669 | 0.030 |
Why?
|
International Cooperation | 1 | 2019 | 1436 | 0.030 |
Why?
|
Carpal Tunnel Syndrome | 1 | 1996 | 304 | 0.030 |
Why?
|
Arthritis, Reactive | 1 | 1992 | 20 | 0.030 |
Why?
|
Pamphlets | 1 | 2012 | 71 | 0.030 |
Why?
|
Iron Overload | 1 | 2015 | 245 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2010 | 10266 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2015 | 753 | 0.030 |
Why?
|
Borrelia burgdorferi Group | 1 | 1992 | 96 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2019 | 2732 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2009 | 10399 | 0.020 |
Why?
|
Erythema Chronicum Migrans | 1 | 1992 | 48 | 0.020 |
Why?
|
Vimentin | 1 | 2012 | 257 | 0.020 |
Why?
|
Cross-Sectional Studies | 4 | 2020 | 26379 | 0.020 |
Why?
|
Interleukins | 1 | 2017 | 796 | 0.020 |
Why?
|
Brain | 1 | 2019 | 27360 | 0.020 |
Why?
|
Retrospective Studies | 6 | 2021 | 81762 | 0.020 |
Why?
|
Immunologic Memory | 1 | 2018 | 1377 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2007 | 4543 | 0.020 |
Why?
|
Pain Threshold | 1 | 2015 | 607 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2022 | 19015 | 0.020 |
Why?
|
Lymphocytes | 1 | 2019 | 2614 | 0.020 |
Why?
|
Acute Disease | 1 | 2022 | 7243 | 0.020 |
Why?
|
Prostatectomy | 1 | 2019 | 1786 | 0.020 |
Why?
|
Self-Help Groups | 1 | 2012 | 194 | 0.020 |
Why?
|
Leukocytes | 1 | 2019 | 2035 | 0.020 |
Why?
|
Community-Institutional Relations | 1 | 2012 | 209 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2018 | 1179 | 0.020 |
Why?
|
Azithromycin | 1 | 1992 | 201 | 0.020 |
Why?
|
Alleles | 3 | 2007 | 6894 | 0.020 |
Why?
|
Histocompatibility Testing | 1 | 1992 | 716 | 0.020 |
Why?
|
Receptors, Collagen | 1 | 2010 | 25 | 0.020 |
Why?
|
Smoking | 1 | 2007 | 9092 | 0.020 |
Why?
|
DNA | 2 | 2015 | 7214 | 0.020 |
Why?
|
Sensation | 1 | 1992 | 336 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2015 | 2923 | 0.020 |
Why?
|
Drug Costs | 2 | 2008 | 1195 | 0.020 |
Why?
|
Aged, 80 and over | 4 | 2019 | 59629 | 0.020 |
Why?
|
Obesity | 1 | 2012 | 13090 | 0.020 |
Why?
|
Social Isolation | 1 | 2012 | 366 | 0.020 |
Why?
|
Logistic Models | 2 | 2015 | 13290 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2008 | 0.020 |
Why?
|
Algorithms | 1 | 2010 | 14164 | 0.020 |
Why?
|
Crohn Disease | 1 | 2022 | 2295 | 0.020 |
Why?
|
Regression Analysis | 2 | 2010 | 6340 | 0.020 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 2010 | 283 | 0.020 |
Why?
|
Telephone | 1 | 2012 | 630 | 0.020 |
Why?
|
Renal Insufficiency | 1 | 2015 | 812 | 0.020 |
Why?
|
Lichen Planus | 1 | 2009 | 70 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15454 | 0.020 |
Why?
|
Syndrome | 1 | 2015 | 3272 | 0.020 |
Why?
|
Anti-Bacterial Agents | 2 | 2002 | 7477 | 0.020 |
Why?
|
Reference Values | 1 | 2015 | 4938 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4260 | 0.020 |
Why?
|
Dermatologic Agents | 1 | 2012 | 313 | 0.020 |
Why?
|
Causality | 1 | 2014 | 1254 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4860 | 0.020 |
Why?
|
Community Health Services | 1 | 2012 | 659 | 0.020 |
Why?
|
Comorbidity | 2 | 2013 | 10590 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 1996 | 1886 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2019 | 3703 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3568 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 1992 | 1528 | 0.020 |
Why?
|
Boston | 2 | 2012 | 9374 | 0.020 |
Why?
|
Risk Factors | 5 | 2022 | 74944 | 0.020 |
Why?
|
Peer Group | 1 | 2012 | 700 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 9384 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2008 | 6316 | 0.020 |
Why?
|
Prognosis | 2 | 2021 | 30010 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2015 | 1890 | 0.020 |
Why?
|
Platelet Activation | 1 | 2010 | 644 | 0.020 |
Why?
|
Focus Groups | 1 | 2012 | 1460 | 0.020 |
Why?
|
Drug Eruptions | 1 | 2009 | 335 | 0.020 |
Why?
|
Interleukin-1 | 1 | 2010 | 1252 | 0.020 |
Why?
|
Antibodies, Bacterial | 1 | 1992 | 1479 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2017 | 2982 | 0.020 |
Why?
|
Canada | 1 | 2011 | 2130 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2005 | 16045 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2784 | 0.020 |
Why?
|
Infusions, Parenteral | 1 | 2005 | 396 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2008 | 5536 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3269 | 0.010 |
Why?
|
Patient Preference | 1 | 2012 | 946 | 0.010 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2005 | 64 | 0.010 |
Why?
|
Cell Movement | 1 | 2017 | 5210 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2015 | 2909 | 0.010 |
Why?
|
Counseling | 1 | 2012 | 1554 | 0.010 |
Why?
|
Medical Records | 1 | 2010 | 1410 | 0.010 |
Why?
|
Drug Utilization Review | 1 | 2005 | 248 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2008 | 879 | 0.010 |
Why?
|
Body Mass Index | 2 | 2012 | 13053 | 0.010 |
Why?
|
False Negative Reactions | 1 | 2005 | 574 | 0.010 |
Why?
|
Time Factors | 3 | 2014 | 40218 | 0.010 |
Why?
|
Prospective Studies | 2 | 2019 | 54926 | 0.010 |
Why?
|
Hematologic Neoplasms | 1 | 2015 | 1907 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2018 | 10474 | 0.010 |
Why?
|
Incidence | 2 | 2011 | 21538 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2012 | 2337 | 0.010 |
Why?
|
Health Services Research | 1 | 2010 | 1815 | 0.010 |
Why?
|
Dietary Supplements | 1 | 2015 | 3445 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2010 | 1738 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2011 | 1791 | 0.010 |
Why?
|
Vitamin D | 1 | 2015 | 3311 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 1992 | 1662 | 0.010 |
Why?
|
Proportional Hazards Models | 2 | 2007 | 12543 | 0.010 |
Why?
|
Quality-Adjusted Life Years | 1 | 2008 | 1741 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2010 | 6231 | 0.010 |
Why?
|
Linear Models | 1 | 2010 | 5884 | 0.010 |
Why?
|
Emotions | 1 | 2012 | 2767 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 1992 | 4568 | 0.010 |
Why?
|
Linkage Disequilibrium | 1 | 2005 | 1997 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12840 | 0.010 |
Why?
|
Occupations | 1 | 2002 | 516 | 0.010 |
Why?
|
Haplotypes | 1 | 2005 | 2722 | 0.010 |
Why?
|
Fibroblasts | 1 | 2010 | 4176 | 0.010 |
Why?
|
Risk | 1 | 2011 | 9613 | 0.010 |
Why?
|
Insurance, Health | 1 | 2011 | 2517 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2010 | 20227 | 0.010 |
Why?
|
Mental Health | 1 | 2012 | 3275 | 0.010 |
Why?
|
Gene Frequency | 1 | 2005 | 3623 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2012 | 4055 | 0.010 |
Why?
|
Gene Expression | 1 | 2010 | 7598 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2010 | 9561 | 0.010 |
Why?
|
Sex Factors | 1 | 2011 | 10632 | 0.010 |
Why?
|
Age Factors | 1 | 2014 | 18412 | 0.010 |
Why?
|
Registries | 1 | 2012 | 8375 | 0.010 |
Why?
|
Insulin | 1 | 2010 | 6607 | 0.010 |
Why?
|
Blood Glucose | 1 | 2010 | 6430 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2011 | 4262 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2012 | 14783 | 0.010 |
Why?
|
Genetic Variation | 1 | 2010 | 6611 | 0.010 |
Why?
|
Health Care Costs | 1 | 2008 | 3239 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2010 | 14488 | 0.010 |
Why?
|
Phenotype | 1 | 1992 | 16726 | 0.010 |
Why?
|
Prevalence | 1 | 2011 | 15869 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2002 | 6229 | 0.010 |
Why?
|
Pregnancy | 1 | 2015 | 30256 | 0.010 |
Why?
|
Mice | 2 | 2010 | 82029 | 0.010 |
Why?
|
Survival Analysis | 1 | 2005 | 10101 | 0.010 |
Why?
|
Genotype | 1 | 2007 | 13045 | 0.010 |
Why?
|
Psychometrics | 1 | 2002 | 3063 | 0.010 |
Why?
|
Massachusetts | 1 | 2005 | 8890 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2010 | 22379 | 0.010 |
Why?
|
Hypertension | 1 | 2011 | 8616 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2010 | 18349 | 0.010 |
Why?
|
Child, Preschool | 1 | 2011 | 42669 | 0.000 |
Why?
|
Animals | 2 | 2010 | 169246 | 0.000 |
Why?
|
Neoplasms | 1 | 1992 | 22371 | 0.000 |
Why?
|
Child | 1 | 2011 | 80917 | 0.000 |
Why?
|